戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 on of the kidney clearance of furosemide and penciclovir.
2 RF 36, weakly sensitized cells to killing by penciclovir.
3 cleoside analogs acyclovir, ganciclovir, and penciclovir.
4 been confirmed as resistant to acyclovir and penciclovir.
5     Additionally, a radiolabeled analogue of penciclovir, [(18)F]FHBG, which is similar in structure
6  by thymidine kinase (TK) assay using 8-(3)H-penciclovir (8-(3)H-PCV) as substrate.
7 the radioactively labeled substrates [8-(3)H]penciclovir ([8-(3)H]PCV), and 8-[(18)F]fluoropenciclovi
8                      Ex vivo substrate (8-3H Penciclovir) accumulation assays in 293T cells expressin
9 nce of adverse events was comparable between penciclovir and placebo groups.
10 -deoxyarabinofuranosyl-5-ethyluracil (FEAU), penciclovir, and 9-[4-fluoro-3-(hydroxymethyl)butyl]guan
11 curred both among patients who first applied penciclovir cream in the prodrome and erythema stages an
12                                              Penciclovir cream is the first treatment to clearly demo
13                                   Topical 1% penciclovir cream or vehicle control cream.
14                              The efficacy of penciclovir cream was apparent when therapy was initiate
15                    Subjects received topical penciclovir for 4 days during successive episodes of rec
16 lovir, an oral form of the purine nucleoside penciclovir, has been shown to inhibit HBV replication.
17 of these mutants to adefovir, lobucavir, and penciclovir in vitro and adefovir in vivo.
18 from these reactivations were susceptible to penciclovir in vitro.
19 mivudine]), and famciclovir (oral prodrug of penciclovir) induced depressions in viremia and intrahep
20             Famciclovir, the oral prodrug of penciclovir, inhibits HBV DNA replication.
21                                              Penciclovir kidney clearance was correlated with iGFR (r
22 e or lamivudine-resistant HBV to lamivudine, penciclovir, or adefovir but instead enhanced viral repl
23                                              Penciclovir (PCV), an antiherpesvirus agent in the same
24 0- and 7-fold more potent than acyclovir and penciclovir, respectively, and TAF was also twice as pot
25 is patient's HSV-2 isolates to acyclovir and penciclovir sensitivity, although resistant virus reappe
26 1.64; P=.003) also resolved more quickly for penciclovir-treated patients compared with patients who
27 lcers, and/or crusts) was 0.7 day faster for penciclovir-treated patients compared with those who rec
28  compared the inhibition constants (K(i)) of penciclovir triphosphate (PCVTP, the active metabolite o
29  triphosphate (FTCTP), adefovir diphosphate, penciclovir triphosphate, and lobucavir triphosphate was
30 f furosemide and famciclovir (metabolized to penciclovir), we calculated their kidney clearances on t
31               Isolates remained sensitive to penciclovir when tested by a plaque reduction assay, and